Your bag is empty.
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog approved by the FDA (under the brand name Egriftsta SV) to reduce excess deep belly (visceral) fat in adults with HIV-associated lipodystrophy. It works by prompting the pituitary gland to naturally release growth hormone, which elevates IGF- 1 and triggers targeted fat breakdown.
Core Benefits
Visceral Fat Reduction: It lowers visceral adipose tissue (deep abdominal fat) by about 15% to 18% over 26 to 52 weeks of treatment.
Improved Lipid Profiles: It helps lower triglycerides and non-HDL cholesterol levels.
Preserved Lean Muscle: Unlike traditional calorie restriction, it helps maintain or support lean muscle mass while targeting fat.
Reduced Liver Fat: Studies show it can decrease excess fat in the liver for patients with nonalcoholic fatty liver disease.